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essential for preserving its effectiveness. Further study is
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Background: Methicillin-resistant S. aureus (MRSA) was
ﬁrst detected in the 1960s, and since that time it has spread
rapidly worldwide, becoming a leading cause of nosocomial
infection. Because MRSA are also resistant to many antibi-
otics, the infections caused by them are particularly difﬁcult
to treat. Indiscriminate use of antibiotics both in hospital
settings and in community may aid in higher prevalence of
MRSA in a country like Nepal.
Methods: A total of 4690 clinical samples were microbi-
ologically processed for the growth of S. aureus in tertairy
referral hospital in Kathmandu, Nepal. Susceptibility testing
was performed in Mueller Hinton agar medium at 35 ◦C.
Results: 264 S. aureus were recovered from the clinical
samples. Among the positive isolates, 73.1% (n = 193) iso-
lates were from outpatients, whereas 26.9% (n = 71) were
from admitted patients. We found 31.1% (82/264) S. aureus
to be methicillin resistant. Among a total of 71 S. aureus
isolated from admitted patients, 46.5% (n = 33) were MRSA
whereas among 193 S. aureus isolated from outpatient,
only 25.4% (n = 49) were MRSA. The association between the
MRSA occurrence in admitted patient as compared to out-
patient was found to be statistically signiﬁcant (62 = 10.26;
P = <0.05). The highest percentage of MRSA was isolated
from sputum 100.0% (2/2), followed by Pus from wound
50.5% (55/109). The distribution of MRSA was highest in
burn ward (75.0%) followed by ICU (66.7%), post opera-
tive ward (57.2%), orthopedic ward (57.1%), neuro-ward
(50.0%) and female surgical ward (41.2%). The antibiotic
resistance of MRSA was highest with Amoxicillin (100.0%)
followed by Cloxacillin (90.2%), Cotrimoxazole (68.3%) and
Erythromycin (61.0%). This pattern varied with Methicillin
Seensitive S. aureus (MSSA). MSSA showed the highest resis-
tance to Cotrimoxazole (42.9%) followed by Gentamicin
(34.6%), Erythromycin (30.8%) and Amoxicillin (23.1%). All
the clinical isolates were sensitive to Vancomycin. MSSA con-
stituted 46.2% (84/182) whereas MRSA constituted 100.0%
(82/82) multidrug resistant (MDR) strains.
Conclusion: MRSA was isolated from variety of clini-
cal specimens. Good communication should be established
among laboratory, hospital wards and physicians for
effective infection control against MRSA. The laboratory per-
sonnel should notify inpatient MRSA cases to the physician
and nurses in charge of the ward to prevent the spread of
MRSA. Prudent use of antibiotics, proper universal precau-
tions, regular environmental screening and good hospital
practices may reduce MRSA colonization and cross infection
in patients.
doi:10.1016/j.ijid.2010.02.391
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Background: Linezolid resistance is rare among
oagulase-negative staphylococci (CoNS). Such isolates
ave been ﬁrstly detected in our institution at November
008. Despite perceived low virulence of CoNS, infection in
ritically ill patients is of potential concern. We performed
n epidemiological and laboratory investigation to assess
his ﬁnding.
Methods: For a 12-month period (November 2008-
ctober 2009), we evaluated all patients harboring
inezolid-resistant (LZ-R) CoNS clinical isolates. Clinical and
aboratory records were reviewed. Species identiﬁcation
nd MIC values determination were performed by Vitek 2
ompact (bioMerieux) and/or Etest (AB Biodisk). Environ-
ental and staff screening was carried out as part of the
nvestigation.
Results: During the study period, 24 patients (16 males,
ean age 45.9± 20.4 years) harboring LZ-R CoNS were
dentiﬁed. A total of 46 LZ-R CoNS clinical isolates were
ecovered. The majority of them (41/46) were isolated from
lood cultures, while the remaining 5 isolates recovered
rom central venous catheter (CVC) tips. Staphylococcus epi-
ermidis was the predominant species (38/46). Linezolid
ICs were >256g/ml for 43/46 isolates. All isolates were
ethicillin-resistant and glycopeptides- and daptomycin-
usceptible. The mean time from admission to LZ-R CoNS
solation was 28± 15.9 days. Records of patients showed
hat 7/24 had >2 comorbidities, 9/24 had prior hospital-
zations and 9/24 had foreign materials placed. At index
ositive culture for LZ-R CoNS, all patients had CVCs, had
eceived prolonged broad-spectrum antibiotic therapy and
6/24 were mechanically ventilated. Prior administration of
inezolid with mean duration 11.2± 7.5 days was noted for
1/24 patients. Overall in-hospital mortality was 25%. There
as no attributed death. Most infections were treated with
eicoplanin. Only 1/58 environmental samples grew LZ-R S.
pidermidis. Screening of ICU-personnel was negative for
Z-R CoNS carriage. Strict infection control measures were
stablished in order to restrain further dissemination of LZ-R
trains, without signiﬁcant reduction of the number of new
ases.
Conclusion: Isolation of LZ-R CoNS, though rare, may be
bserved in critically ill patients after prolonged admin-
stration of linezolid. Intense infection control measures,
ontinuous surveillance and judicious use of linezolid aresolates.
oi:10.1016/j.ijid.2010.02.392
